ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1690

Butyric Acid Suppresses Migration of Human Monocyte Derived Dendritc Cell by Inhibiting Actin Polymerization via mDia1 Inhibition

Takumi Nagamoto1, takaichi okano2, Yoshikazu Fujikawa3, Yuzuru Yamamoto2, Hirotaka Yamada2, Yo Ueda2, Sho Sendo4 and Jun saegusa2, 1Kobe University, Kobe, Japan, 2Kobe University, Rheumatology, Kobe, Japan, 3Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan, 4University California, San Diego (UCSD), La Jolla, CA

Meeting: ACR Convergence 2022

Keywords: Dendritic cells, Inflammation, innate immunity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Innate Immunity Poster: Basic and Translational Science

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Butyric acid is known to improve chronic inflammation such as inflammatory bowel disease and arthritis. Dendritic cells activate in inflammatory condition, migrate to regional lymph nodes, and activate naive T cells.

In this study, we investigated the effect of butyric acid on the migration ability of monocyte-derived dendritic cells (moDC).

Methods: Human CD14+ Monocytes were purified by positive selection from PBMC using CD14 magnetic beads. Cells were cultured in the presence of GM-CSF (50 ng/ml) and IL-4 (20 ng/ml) for 5 days. After culturing for 5 days, cells were matured with LPS (1ug/ml) for 24 hours. Butyric acid was administered at different dose or period. Surface antigen on moDC was analyzed by flow cytometry (BD FACS VERSETM). Migration assay was performed on Boyden chamber CytoSelectTM 24-Well Cell Migration Assay (5um). Actin was stained with Alexa Fluor® 488 Phalloidin before and after migration assay. After administration with butyric acid assigned to each period and concentration, moDC were lysed for western blot analysis for evaluating signaling. Chemiluminescent signals were detected and calculated by AmershamTM Imager.

Results: We demonstrated that butyric acid decreased the CCR7 expression of moDC, which has a key role in DC homing to the lymph nodes and intestinal Peyer’s patches. We also showed that butyric acid decreased the migration ability of moDC. Furthermore, moDCs cultured with butyric acid showed a round shape and poor formation of dendrites and pseudopodia. Then we studied the effect of butyric acid on cytoskeleton, which plays an important role in migration and pseudopodia formation of DCs. Polymerized Actin (F-Actin) staining revealed that butyrate suppressed actin polymerization of moDC in a dose dependent manner. CDC42 works important role of lamellipodia and membrane protrusions. RhoA is upstream of mDia1, and mDia1 was reported to accelerate actin nucleation and elongation. We revealed that butyric acid decreased the protein expression of mDia1, RhoA, and CDC42, while beta actin was not downregulated, by Western blot analysis.

Finally, we administered Rho/Rac/CDC42 activator I (CN04), it robustly increases the level of GTP-bound RhoA, Rac1 and CDC42 by deamidating glutamin-63 of Rho and glutamin 61 of Rac and CDC42 in their respective Switch II resions. CN04 restored the migration ability od moDC reduced by butyric acid.

In summary, butyric acid changed cell morphology and decreased migration ability by inhibiting Actin polymerization. Butyric acid suppressed the expression of RhoA, CDC42 and mDia1 and inhibited polymerization of Actin. CN04 abrogated the inhibitory effect of butyric aci on moDC migration. Butyric acid impairs antigen presentation by inhibiting Dendritic Cell migraion and maybe involved in tolerance such as in the intestinal tract.

Conclusion: Butyric acid suppresses migration of monocyte derived Dendritic Cell by inhibiting Actin polymerization via mDia1 inhibition. Butyric acid impairs antigen presentation by inhibiting Dendritic Cell migraion and may be involved in tolerance.

Supporting image 1

Butyric acid inhibited migration of moDC.

a) Butyric acid inhibited migration of moDC for CCL21.

b) Butyric acid inhibited migration of moDC for FBS.

All data are presented as mean±sem.
P < 0.05; **P < 0.01, *** P < 0.001 Based on Turky

Supporting image 2

Butyric acid inhibited Actin polymerization.

a, b) F-Actin staing by Alexa flour 488 conjugated phalloidin revealed that Butyric acid changed cell morphology. moDC cultured with butyric acid showed a round shape and poor formation of dendrites and pseudopodia.

c, d) Butyric acid inhibited Actin polymerization of moDC especially after migration. MFI was measured by FACS VERSE.

All data are presented as mean±sem.
P < 0.05; **P < 0.01, *** P < 0.001 Based on Turky

Supporting image 3

Butyric acid suppressed the expression of CDC42, mDia1, and RhoA.
a, b, c, d) Western blot analysis revealed that butyric acid suppressed the expression of CDC42, mDia1, and RhoA, while beta Actin was not downregulated.

Chemiluminescent signals were detected and calculated by Amersham Imager.

All data are presented as mean±sem.
P < 0.05; **P < 0.01, *** P < 0.001 Based on Turky


Disclosures: T. Nagamoto, None; t. okano, None; Y. Fujikawa, None; Y. Yamamoto, None; H. Yamada, None; Y. Ueda, None; S. Sendo, None; J. saegusa, None.

To cite this abstract in AMA style:

Nagamoto T, okano t, Fujikawa Y, Yamamoto Y, Yamada H, Ueda Y, Sendo S, saegusa J. Butyric Acid Suppresses Migration of Human Monocyte Derived Dendritc Cell by Inhibiting Actin Polymerization via mDia1 Inhibition [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/butyric-acid-suppresses-migration-of-human-monocyte-derived-dendritc-cell-by-inhibiting-actin-polymerization-via-mdia1-inhibition/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/butyric-acid-suppresses-migration-of-human-monocyte-derived-dendritc-cell-by-inhibiting-actin-polymerization-via-mdia1-inhibition/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology